Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated approval pathway for nomlabofusp in Friedreich’s ataxia. The news removes a key overhang and reinforces Citi’s view of favorable risk/reward for the shares, which are trading well below cash, the analyst tells investors in a research note. The firm would be buyers on the post-earnings weakness and keeps a Buy rating on the name with a $14 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue